Cabergoline Oral: Uses, Dosing, and Precautions
Cabergoline guidance for inhibition or suppression of lactation after fetal or neonatal loss, with postpartum safety restrictions.
Also searched as
Source reviewed
source date listed on the source page
Guide category
Oral drugs
Safety boundary
Prescription medicine information for clinician-guided use.
Kenza Health Hub presents this medicine page as structured health education. Check dose, route, interactions, pregnancy or breast-feeding considerations, and local protocol with a qualified clinician or pharmacist. Read our medical editorial policy.
Therapeutic action
Long-lasting lactation inhibitor.
Indications
Inhibition of lactation or suppression of established lactation in case of intrauterine foetal death or neonatal death.
Forms and strengths
- 0.5 mg scored tablet.
Dose and duration
Lactation inhibition
- 1 mg single dose on the first day post-partum.
Lactation suppression
- 0.25 mg every 12 hours for 2 days.
Contra-indications, adverse effects, precautions
- Do not administer to patients with postpartum hypertension or psychosis, preeclampsia, valvulopathy, or a history of pulmonary, retroperitoneal, or pericardial fibrosis.
- May cause hypotension, valvulopathy, dizziness, headache, nausea, drowsiness, and hallucinations.
- Do not combine with chlorpromazine, haloperidol, metoclopramide, or promethazine because the effect of cabergoline is antagonised.
- Do not combine with methylergometrine because of the risk of vasoconstriction and hypertensive crisis.
- Do not combine with macrolides because the effect of cabergoline is increased.
- Pregnancy: contraindicated.
Source
MSF Essential drugs practical guidelines (January 2026)
This page combines source-derived medicine reference sections with Kenza editorial context, while leaving out the Storage and Remarks sections from the source batch.
Rate this guide
Be the first to rate this guide.